Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide added to R-CHOP vs R-CHOP in high-risk newly diagnosed DLBCL
jRCT2071220021Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Tafasitamab + lenalidomide + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: PFS-INV. Started Jul 2022; status: active, not recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2071220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220021.